Biosimilar Denosumab Could Reshape Access, Costs in Osteoporosis Care: Edward Li, PharmD

September 01, 2026

Sandoz's Edward Li explains how biosimilar denosumab pricing could reshape cost-effectiveness, payer access, and gaps in osteoporosis care.

Step Therapy to Biosimilars, Branded Anti-VEGF Costs More, Data Show

August 31, 2026

Natalizumab Biosimilar Shows Limited Cost-Effectiveness in MS

August 28, 2026

Nonmedical Adalimumab Biosimilar Switch Maintains Disease Control in Pediatric IBD

August 24, 2026

Abbreviated Biologics Pathway Could Revive Biosimilar Competition

August 19, 2026

Featured Content

CFB podcast banner

How Streamlining Development Can Save the US Biosimilar Industry

pharmacist counting medications

AAM White Paper Breaks Down Drug Shortage Crisis: Causes and Solutions

several filled syringes in different sizes and colors

Samsung Bioepis Report Proves Lower Biosimilar Prices Correlate With Greater Market Share

red liquid in a vial

Authors Suggest Major Policy Shifts to Boost Biosimilar Development, Accessibility

Rituximab Biosimilars Show Comparable 6-Month Outcomes in AAV

August 14th 2026

By Brooke McCormick

Rituximab biosimilars showed no significant 6-month differences vs the originator in antineutrophil cytoplasmic antibody–associated vasculitis (AAV).

Adalimumab Biosimilar Sustains Efficacy After Switch in Saudi Cohort

August 11th 2026

By Giuliana Grossi

Saudi real-world study finds adalimumab biosimilar switching preserves efficacy and safety, with full response in patients with HS.

Analytical Characterization Supports Confidence in Monoclonal Antibody Biosimilars

August 6th 2026

By Brooke McCormick

Analytical characterization supports monoclonal antibody biosimilar approvals and may reduce clinical testing needs, researchers found.

Biosimilar Denosumab Shows Cost-Effectiveness Over Bisphosphonates in PMO

August 4th 2026

By Skylar Jeremias

Biosimilar denosumab cleared a $150,000 per QALY cost-effectiveness threshold against bisphosphonates for high-risk PMO, but not always at $100,000.

Biosimilars Round Up: July 2026

August 4th 2026

By Sabrina McCrear

Congress advances biosimilar bills as new data emerge on romosozumab, tirzepatide, and ustekinumab biosimilar development.

Denosumab Biosimilar KN012 Matches Reference Drug in Phase 3 Osteoporosis Trial

July 30th 2026

By Pearl Steinzor

KN012 achieved BMD equivalence with US-approved denosumab in postmenopausal women in China.

India's Anti-VEGF Biosimilars Cut Costs, Expand Access

July 30th 2026

By Brooke McCormick

Anti-VEGF biosimilars in India matched reference therapy, lowered costs, and improved treatment access and adherence for retinal diseases.

Eculizumab Biosimilar Shows Durable Benefit in Long-Term aHUS

July 29th 2026

By Pearl Steinzor

A 50-patient study found sustained platelet recovery and low thrombotic microangiopathy rates through 52 weeks of biosimilar therapy, with favorable safety.

Biosimilar Bills Gain Steam in Congress, But Key Reforms Still Wait

July 23rd 2026

By Skylar Jeremias

Congress fast-tracks biosimilar bills to cut drug and insulin costs, while patent, rebate, and reimbursement roadblocks still stall competition.

Aflibercept Biosimilar SB15 Shows Real-World Efficacy Across Retinal Diseases

July 22nd 2026

By Pearl Steinzor

Aflibercept biosimilar SB15 improved retinal anatomy while preserving vision in both treatment-naïve and switching patients with nAMD, RVO, and DME.

Advertisement

Advertisement